Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A | P11388 | 1/20 | 0.39 |
| ▸ | NAAA | Q02083 | 5/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | BTN3A1 | O00481 | 1/20 | 0.33 |
| ▸ | ELANE | P08246 | 3/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | GFER | P55789 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26558108 | 0.90 | SMYD2 (0.34) | NAAAALDH1A1ELANEMEN1KMT2A | |
| SCHEMBL26558100 | 0.90 | ALDH1A1 (0.36) | NAAAALDH1A1ELANEMEN1KMT2A | |
| SCHEMBL26558101 | 0.87 | NAAA (0.36) | NAAAALDH1A1ELANEMEN1KMT2A | |
| SCHEMBL26557776 | 0.86 | ALDH1A1 (0.38) | NAAAALDH1A1ELANEMEN1KMT2A | |
| SCHEMBL26558103 | 0.86 | ALDH1A1 (0.35) | NAAAALDH1A1ELANEMEN1KMT2A | |
| SCHEMBL26558118 | 0.85 | ALDH1A1 (0.34) | TOP2ANAAAALDH1A1ELANEMEN1 | |
| SCHEMBL26558150 | 0.83 | NAAA (0.38) | NAAAALDH1A1MEN1KMT2AHSD17B10 | |
| SCHEMBL26558122 | 0.82 | TOP2A (0.33) | TOP2ACYP3A4 | |
| SCHEMBL26558133 | 0.81 | NAAA (0.38) | NAAAALDH1A1MEN1KMT2AHSD17B10 | |
| SCHEMBL26558087 | 0.81 | TOP2A (0.37) | TOP2ACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230331751-A1 | STEREOSELECTIVE MANUFACTURE OF SELECTED PURINE PHOSPHORAMIDATES | Atea Pharmaceuticals, Inc. (US) | 2023-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230331751-A1 | STEREOSELECTIVE MANUFACTURE OF SELECTED PURINE PHOSPHORAMIDATES | NUDT1, PNP, ATIC | TOP2A 3137/4885NAAA 489/4885ALDH1A1 946/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.